KLHL7 promotes hepatocellular carcinoma progression and molecular therapy resistance by degrading RASA2

Hepatocellular carcinoma (HCC) is a common aggressive tumor with a poor prognosis, and patients often seem to be refractory to the use of therapeutic drugs. In this study, we found that the KLHL7 expression was upregulated in HCC that was associated with poor patient prognosis. KLHL7 has been found...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lin, Li, Yun, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291331/
https://www.ncbi.nlm.nih.gov/pubmed/37378318
http://dx.doi.org/10.1016/j.isci.2023.106914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291331/
https://www.ncbi.nlm.nih.gov/pubmed/37378318
http://dx.doi.org/10.1016/j.isci.2023.106914

Ejemplares similares